Literature DB >> 803246

Pyrido(2,3-d)pyrimidine antibacterial agents. 3. 8-Alkyl- and 8-vinyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)pyrido(2,3-d)pyrimidine-6-carboxylic acids and their derivatives.

J Matsumoto, S Minami.   

Abstract

The preparation and antibacterial activity of a series of the title compounds (21-73) are described. These compounds were prepared from the 2-methylthio derivatives 2 and 3 via the 2-methylthio-8-substituted compounds 4-20; compounds 4-20 easily underwent displacement reactions with a variety of piperazines to afford 2-(4-substituted or unsubstituted 1-piperazinyl) derivatives 21-56, of which 21, 22, 27 and 51 with unsubstituted piperazinyl group at position 2 are converted subsequently into 57-73 by alkylation, acylation, sulfonylation, or addition of isocyanates to the piperazine nitrogen. The hexahydro-1H-1,4-diazepinyl analog 74 was also prepared. The most active members in this series of compounds were found to be 8-ethyl- and 8-vinyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)pyrido(2,3-d)pyrimidine-6-carboxylic acids (22 and 51), both of which are more active in vitro and in vivo against gram-negative bacteria, including Pseudomonas aeruginosa, than piromidic acid (1). Structure-activity relationships are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 803246     DOI: 10.1021/jm00235a017

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Inhibition of conjugal transfer of R plasmids by pipemidic acid and related compounds.

Authors:  S Nakamura; S Inoue; M Shimizu; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

3.  Determination of pipemidic acid in plasma by normal-phase high-pressure liquid chromatography.

Authors:  H Ito; M Inoue; M Morikawa; M Tsuboi; K Oka
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

4.  Pipemidic acid: its activities against various experimental infections.

Authors:  M Shimizu; Y Takdase; S Nakamura; H Katae; A Minami
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

5.  Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties.

Authors:  M Shimizu; Y Takase; S Nakamura; H Katae; A Minami
Journal:  Antimicrob Agents Chemother       Date:  1975-08       Impact factor: 5.191

6.  Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

Authors:  S Inoue; T Ohue; J Yamagishi; S Nakamura; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

7.  Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; L M Yamanaka; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

8.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

9.  Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.

Authors:  S Nakamura; K Nakata; H Katae; A Minami; S Kashimoto; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

10.  β-Cyclodextrin inclusion complex to improve physicochemical properties of pipemidic acid: characterization and bioactivity evaluation.

Authors:  Rosa Iacovino; Filomena Rapuano; Jolanda Valentina Caso; Agostino Russo; Margherita Lavorgna; Chiara Russo; Marina Isidori; Luigi Russo; Gaetano Malgieri; Carla Isernia
Journal:  Int J Mol Sci       Date:  2013-06-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.